Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced…
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced…
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced…
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage…
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage…
Biostat STR(R) Bioreactor Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and…
Biostat STR(R) Bioreactor Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and…
SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc….
SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc….
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax…
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax…
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primates…
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primates…
The New Fruit-Forward Infused Pre-Roll Series from Best-Selling Cannabis Brand Good Supply Now Available Across…
The New Fruit-Forward Infused Pre-Roll Series from Best-Selling Cannabis Brand Good Supply Now Available Across…
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory…
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory…